Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Avoro Ventures Adds Mark Chin as a Partner

NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts. Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development. Prior to joining Avoro Ventures, Mark was …

Read More

Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution. COPENHAGEN, DENMARK and BOSTON, MASS., US – February 21, 2023 Hemab Therapeutics, a clinical-stage biotechnology company developing …

Read More

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

LOS ANGELES, Sept. 22, 2022 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of …

Read More

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies Lead program targets Parkinson’s disease and all forms of Gaucher disease CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that …

Read More